Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01969695 | An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma | completed | Phase 1 | 11 | AbbVieINDUSTRY | 1 | Dec 19, 2019 | clinicaltrials |
| NCT01134341 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 34 | Acrotech Biopharma Inc.INDUSTRY | 2 | Dec 18, 2019 | clinicaltrials |
| NCT00450814 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 48 | Mayo ClinicOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02057640 | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Jason ValentOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01503242 | 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00861510 | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | completed | Phase 1 | 16 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | completed | Phase 1 / Phase 2 | 9 | Robert LowskyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02189343 | Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | completed | Phase 1 | 16 | CelgeneINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00555100 | Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01568294 | Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01937442 | Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma | completed | Phase 1 | 7 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT00005792 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | completed | Phase 1 | 131 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01351935 | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | completed | Phase 1 | 113 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01453504 | Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma(HD-R3i) | completed | Phase 1 / Phase 2 | 73 | University of CologneOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02006485 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | completed | Phase 1 | 160 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00834665 | Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | completed | Phase 1 | 59 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01142232 | Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | completed | Phase 1 / Phase 2 | 60 | Attaya SuvannasankhaOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01076543 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02215967 | Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2019 | clinicaltrials |
| NCT02164006 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | completed | Phase 1 | 16 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02518113 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | completed | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 11, 2019 | clinicaltrials |
| NCT02822586 | TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | completed | Phase 1 | 5 | Virginia Commonwealth UniversityOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02453087 | A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 66 | Hoffmann-La RocheINDUSTRY | 1 | Aug 29, 2019 | clinicaltrials |
| NCT01676831 | Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 / Phase 2 | 13 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01001442 | Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01363817 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 1 | 31 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT02950220 | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 2 | Kami MaddocksOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01699152 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 | 16 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 25, 2019 | clinicaltrials |
| NCT02809573 | Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | completed | Phase 1 | 30 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01638936 | BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01372540 | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00850057 | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02811822 | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | Phase 1 | 10 | GlycoMimetics IncorporatedINDUSTRY | 4 | Jul 10, 2019 | clinicaltrials |
| NCT02401048 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | completed | Phase 1 / Phase 2 | 61 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 10, 2019 | clinicaltrials |
| NCT00916058 | Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 57 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00880815 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | completed | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT02426723 | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | completed | Phase 1 | 25 | JW PharmaceuticalINDUSTRY | 2 | May 17, 2019 | clinicaltrials |
| NCT01800838 | Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 11 | Kevin Cooper MDOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT02665650 | Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 | 30 | Affimed GmbHINDUSTRY | 2 | May 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 20, 2019source: clinicaltrials